dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Epithelial sodium channel (ENaC) (type: lgic)
Target: ENaC&alpha;&beta;&gamma;

Ligand: S3969 (Synthetic organic)
Interaction type: Activator
Action: None
Ligand approved: no
Primary target: no
Median affinity: 5.900000095367432 pEC50
Reference (Journal): Small molecule activator of the human epithelial sodium channel.
Published in: J Biol Chem

Ligand: triamterene (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1964)
Primary target: yes
Median affinity: 5.300000190734863 pIC50
Reference (Journal): Mutations in the epithelial Na+ channel ENaC outer pore disrupt amiloride block by increasing its dissociation rate.
Published in: Mol Pharmacol

Ligand: triamterene (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1964)
Primary target: yes
Median affinity: 5.300000190734863 pIC50
Reference (Journal): Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits.
Published in: Nature

Ligand: amiloride (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: yes
Approval source: FDA (1981)
Primary target: yes
Median affinity:  pIC50

Ligand: benzamil (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50

Ligand: P552-02 (Synthetic organic)
Interaction type: Channel blocker
Action: None
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50

Ligand: BI1265162 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.520000457763672 pIC50
Reference (Patent): Novel annelated phenoxyacetamides
Target family: Erk7 subfamily (type: enzyme)
Target: mitogen-activated protein kinase 15

Ligand: BS-194 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.480000019073486 pIC50
Reference (Journal): A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration.
Published in: J Med Chem
Target family: ERK subfamily (type: enzyme)
Target: mitogen-activated protein kinase 3

Ligand: ERK inhibitor II (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.389999866485596 pKi
Reference (Journal): Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex.
Published in: Biochem Biophys Res Commun

Ligand: MK-8353 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.639999866485596 pIC50
Reference (Journal): Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.
Published in: JCI Insight

Ligand: ravoxertinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Patent): Serine/threonine kinase inhibitors

Ligand: ravoxertinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  pIC50
Reference (Journal): Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.
Published in: J Med Chem

Ligand: ulixertinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.520000457763672 pIC50
Reference (Journal): Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2.
Published in: J Med Chem
Target family: ERK subfamily (type: enzyme)
Target: mitogen-activated protein kinase 7

Ligand: AX15836 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.100000381469727 pIC50
Reference (Journal): ERK5 kinase activity is dispensable for cellular immune response and proliferation.
Published in: Proc Natl Acad Sci U S A

Ligand: BAY-885 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.460000038146973 pIC50
Reference (Journal): Discovery and Characterization of the Potent and Highly Selective (Piperidin-4-yl)pyrido[3,2- d]pyrimidine Based in Vitro Probe BAY-885 for the Kinase ERK5.
Published in: J Med Chem

Ligand: BIX02188 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.090000152587891 pIC50
Reference (Journal): Identification of pharmacological inhibitors of the MEK5/ERK5 pathway.
Published in: Biochem Biophys Res Commun

Ligand: BIX02189 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.230000019073486 pIC50
Reference (Journal): Identification of pharmacological inhibitors of the MEK5/ERK5 pathway.
Published in: Biochem Biophys Res Commun

Ligand: DCLK1-IN-1 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.739999771118164 pIC50
Reference (Journal): Discovery of a selective inhibitor of doublecortin like kinase 1.
Published in: Nat Chem Biol

Ligand: XMD17-109 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.789999961853027 pIC50
Reference (Journal): Structural determinants for ERK5 (MAPK7) and leucine rich repeat kinase 2 activities of benzo[e]pyrimido-[5,4-b]diazepine-6(11H)-ones.
Published in: Eur J Med Chem

Ligand: XMD8-92 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.099999904632568 pKd
Reference (Journal): Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.
Published in: Cancer Cell
Target family: Eta subfamily (type: enzyme)
Target: protein kinase C eta

Ligand: 10-Me-Aplog-1 (Synthetic organic)
Interaction type: Activator
Action: Activation
Ligand approved: no
Primary target: no
Median affinity: 9.350000381469727 pKi
Reference (Journal): Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity.
Published in: J Med Chem

Ligand: balanol (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.520000457763672 pIC50
Reference (Journal): Synthesis and protein kinase C inhibitory activities of acyclic balanol analogs that are highly selective for protein kinase C over protein kinase A.
Published in: J Med Chem

Ligand: sotrastaurin (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.210000038146973 pIC50
Reference (Journal): Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective inhibitor of protein kinase C isotypes.
Published in: J Med Chem
Target family: Exchange proteins activated by cyclic AMP (EPACs) (type: enzyme)
Target: Rap guanine nucleotide exchange factor 3

Ligand: CE3F4 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -

Ligand: ESI-09 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.489999771118164 pIC50
Reference (Journal): A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion.
Published in: Mol Pharmacol
Target family: Exchange proteins activated by cyclic AMP (EPACs) (type: enzyme)
Target: Rap guanine nucleotide exchange factor 4

Ligand: ESI-09 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion.
Published in: Mol Pharmacol

Ligand: ESI-09 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Recent advances in the discovery of small molecules targeting exchange proteins directly activated by cAMP (EPAC).
Published in: J Med Chem

Ligand: HJC 0350 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.5 pIC50
Reference (Journal): Identification and characterization of small molecules as potent and specific EPAC2 antagonists.
Published in: J Med Chem
Target family: Fak family (type: enzyme)
Target: protein tyrosine kinase 2

Ligand: CEP-37440 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).
Published in: J Med Chem

Ligand: compound 30 [PMID: 23414845] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 6.190000057220459 pIC50
Reference (Journal): Structure-based discovery of cellular-active allosteric inhibitors of FAK.
Published in: Bioorg Med Chem Lett

Ligand: conteltinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Patent): 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS

Ligand: ENMD-2076 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.260000228881836 pIC50
Reference (Journal): Discovery and development of aurora kinase inhibitors as anticancer agents.
Published in: J Med Chem

Ligand: narmafotinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.680000305175781 pKd
Reference (Patent): Selective FAK inhibitors

Ligand: NVP-TAE 226 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.260000228881836 pIC50
Reference (Journal): A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.
Published in: Mol Carcinog

Ligand: NVP-TAE 226 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.260000228881836 pIC50
Reference (Journal): Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Published in: Mol Cancer Ther

Ligand: PF-562271 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.819999694824219 pIC50
Reference (Journal): Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Published in: Cancer Res

Ligand: VS-4718 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 8.819999694824219 pIC50
Reference (Journal): PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments.
Published in: Cancer Biol Ther

Ligand: YHJ1039 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.149999618530273 pIC50
Reference (Journal): Identification of Thieno[3,2-<i>d</i>]pyrimidine Derivatives as Dual Inhibitors of Focal Adhesion Kinase and FMS-like Tyrosine Kinase 3.
Published in: J Med Chem
Target family: Fak family (type: enzyme)
Target: protein tyrosine kinase 2 beta

Ligand: aloisine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.03000020980835 pKi
Reference (Journal): Identification of binding specificity-determining features in protein families.
Published in: J Med Chem

Ligand: conteltinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.699999809265137 pIC50
Reference (Patent): 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS

Ligand: NVP-TAE 226 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Published in: Mol Cancer Ther

Ligand: PF-562271 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.889999866485596 pIC50
Reference (Journal): Antitumor activity and pharmacology of a selective focal adhesion kinase inhibitor, PF-562,271.
Published in: Cancer Res
Target family: Fatty acid-binding proteins (type: other_protein)
Target: fatty acid binding protein 1

Ligand: fenofibrate (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1993), EMA (2011)
Primary target: no
Median affinity: 7.619999885559082 pKi
Reference (Journal): Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Published in: J Med Chem
Target family: Fatty acid-binding proteins (type: other_protein)
Target: retinol binding protein 4

Ligand: A1120 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.849999904632568 pIC50
Reference (Journal): Structure-assisted discovery of the first non-retinoid ligands for Retinol-Binding Protein 4.
Published in: Bioorg Med Chem Lett
Target family: Fatty acid-binding proteins (type: other_protein)
Target: fatty acid binding protein 5

Ligand: compound 13 [PMID: 17502136] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKi
Reference (Journal): Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
Published in: Bioorg Med Chem Lett
Target family: Fatty acid-binding proteins (type: other_protein)
Target: fatty acid binding protein 4

Ligand: HTS01037 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.170000076293945 pKi
Reference (Journal): Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.
Published in: J Med Chem

Ligand: compound 13 [PMID: 17502136] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pKi
Reference (Journal): Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
Published in: Bioorg Med Chem Lett

Ligand: HM50316 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9 pKi
Reference (Journal): New aromatic substituted pyrazoles as selective inhibitors of human adipocyte fatty acid-binding protein.
Published in: Bioorg Med Chem Lett

Ligand: bindarit (Synthetic organic)
Interaction type: Inhibitor
Action: Binding
Ligand approved: no
Primary target: no
Median affinity: 4.71999979019165 pKi
Reference (Journal): The anti-inflammatory agent bindarit acts as a modulator of fatty acid-binding protein 4 in human monocytic cells.
Published in: Sci Rep
Target family: Fatty acid-binding proteins (type: other_protein)
Target: fatty acid binding protein 3

Ligand: compound 13 [PMID: 17502136] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pKi
Reference (Journal): Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
Published in: Bioorg Med Chem Lett
Target family: Fatty acid-binding proteins (type: other_protein)
Target: fatty acid binding protein 1

Ligand: HTS01037 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.090000152587891 pKi
Reference (Journal): Identification and characterization of a small molecule inhibitor of Fatty Acid binding proteins.
Published in: J Med Chem

Ligand: fenofibric acid (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.480000019073486 pKi
Reference (Journal): Characterization of the drug binding specificity of rat liver fatty acid binding protein.
Published in: J Med Chem
Target family: Fc epsilon receptors (type: catalytic_receptor)
Target: Fc fragment of IgE receptor Ia

Ligand: IgE heavy chain (Peptide)
Interaction type: Agonist
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 10 pKd
Target family: Fc epsilon receptors (type: catalytic_receptor)
Target: Fc fragment of IgE receptor II

Ligand: IgE heavy chain (Peptide)
Interaction type: Agonist
Action: Binding
Ligand approved: no
Primary target: yes
Median affinity: 7 pKd
Target family: Fer family (type: enzyme)
Target: FER tyrosine kinase

Ligand: compound 25b [PMID: 22564207] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.070000171661377 pIC50
Reference (Journal): Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Published in: J Med Chem

Ligand: compound 8e [PMID: 24432909] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.699999809265137 pIC50
Reference (Journal): Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Published in: J Med Chem

Ligand: DS21360717 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 9.3100004196167 pIC50
Reference (Journal): Discovery of Novel Pyrido-pyridazinone Derivatives as FER Tyrosine Kinase Inhibitors with Antitumor Activity.
Published in: ACS Med Chem Lett

Ligand: Ro3280 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.28000020980835 pKd
Reference (Journal): Identification of novel, potent and selective inhibitors of Polo-like kinase 1.
Published in: Bioorg Med Chem Lett
Target family: Fer family (type: enzyme)
Target: FES proto-oncogene, tyrosine kinase

Ligand: compound 25b [PMID: 22564207] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7 pIC50
Reference (Journal): Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.
Published in: J Med Chem

Ligand: compound 8e [PMID: 24432909] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.300000190734863 pIC50
Reference (Journal): Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Published in: J Med Chem

Ligand: lorlatinib (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2018), EMA (2019)
Primary target: no
Median affinity: 8.220000267028809 pIC50
Reference (Journal): Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Published in: J Med Chem
Target family: Folate biosynthesis enzymes (type: other_protein)
Target: Plasmodium falciparum hydroxymethyldihydropterin pyrophosphokinase-dihydropteroate synthase

Ligand: dapsone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1979), UK (1988)
Primary target: no
Median affinity: 5.21999979019165 pKi
Reference (Journal): Inhibition of Plasmodium falciparum dihydropteroate synthetase and growth in vitro by sulfa drugs.
Published in: Antimicrob Agents Chemother

Ligand: sulfadoxine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1981) in combination with pyrimethamine
Primary target: no
Median affinity: 7.139999866485596 pIC50
Reference (Journal): Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization.
Published in: Mol Microbiol

Ligand: sulfadoxine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1981) in combination with pyrimethamine
Primary target: no
Median affinity: 5.400000095367432 pIC50
Reference (Journal): Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization.
Published in: Mol Microbiol

Ligand: sulfadoxine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1981) in combination with pyrimethamine
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Journal): Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization.
Published in: Mol Microbiol

Ligand: sulfadoxine (Synthetic organic)
Interaction type: None
Action: None
Ligand approved: yes
Approval source: FDA (1981) in combination with pyrimethamine
Primary target: no
Median affinity: 6.650000095367432 pIC50
Reference (Journal): Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization.
Published in: Mol Microbiol